News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alla Chem Announces Initiation Of Phase I Clinical Studies Of ONC1-13B, A New Effective Anti-Androgen For The Treatment Of Prostate Cancers


5/16/2014 11:20:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

May 14, 2014 — AllaChem, LLC announces initiation of Phase 1 clinical study of ONC1-13B in patients with metastatic Castration Resistant Prostate Cancer (mCRPC). ONC1-13B is a next in-class small molecule anti-androgen for the treatment of Prostate Cancers. In preclinical studies, it was shown that ONC1-13B efficiently inhibits androgen receptor signaling pathway by preventing binding to androgens, blocking its nuclear translocation and transcriptional co-activator complex formation (A. V. Ivachtchenko et al. Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J. Cancer 2014, 5(2), 133-142).

The Phase 1 open-label, dose-escalation clinical study will evaluate the safety, tolerability and pharmacokinetics of ONC1-13B in patients with mCPRC. Pharmacokinetics will be investigated after single and multiple (for 3 weeks) doses. To determine maximal tolerated dose ONC1-13B will be administered once daily in doses up to 320 mg (40, 80, 160, 240 and 320 mg/day) up to 72 weeks. Up to 40 patients will be included in the trial. Other endpoints include assessment of effect of ONC1-13B on the disease progression (according to the RECIST 1.1criteria) and on PSA (prostate-specific antigen) expression.

Contact:

Alena Ivachtchenko
Director, Business Development
AllaChem, LLC
Tel: 786-617-4449
Email: alena.ivachtchenko@allachem.com
www.allachem.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Alla Chem
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES